STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[144] Axsome Therapeutics, Inc SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Form 144 Notice Filing for Axsome Therapeutics (NASDAQ: AXSM) details proposed sale of securities by insider Hunter R. Murdock. The filing indicates a planned sale of 6,014 shares of common stock with an aggregate market value of $602,101, to be executed through Charles Schwab & Co.

The shares were acquired through an Employee Stock Option Exercise on June 23, 2025, with payment made via a cashless exercise through broker. The filing reveals significant recent insider trading activity by the same individual over the past three months:

  • June 20, 2025: 7,500 shares sold for $768,503
  • June 18, 2025: 7,500 shares sold for $756,729
  • June 17, 2025: 7,500 shares sold for $751,975
  • June 16, 2025: 7,500 shares sold for $768,154

Total outstanding shares reported: 49,236,365. The proposed sale represents a continuation of systematic insider selling pattern, with approximately 30,000 shares sold in the preceding month.

Positive

  • None.

Negative

  • Insider Hunter R. Murdock executed multiple significant sales totaling 30,000 shares worth approximately $3 million over a 5-day period in June 2025, indicating substantial selling pressure from management
  • The insider is planning an additional sale of 6,014 shares worth approximately $602,101, continuing the selling pattern

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

How many AXSM shares were sold by Hunter R. Murdock in June 2025?

According to the Form 144 filing, Hunter R. Murdock sold a total of 30,000 shares of Axsome Therapeutics (AXSM) across four transactions between June 16-20, 2025, generating total gross proceeds of approximately $3.045 million.

What is the proposed sale amount in AXSM's latest Form 144 filing?

The Form 144 filing indicates a proposed sale of 6,014 shares of AXSM common stock with an aggregate market value of $602,101.00, to be executed through Charles Schwab & Co., Inc. on the NASDAQ exchange around June 23, 2025.

How did the AXSM insider acquire the shares being sold?

The shares were acquired through an Employee Stock Option Exercise from Axsome Therapeutics, Inc. on June 23, 2025, with payment made through a broker payment for cashless exercise arrangement.

What was AXSM's total shares outstanding according to the June 2025 Form 144?

According to the Form 144 filing, Axsome Therapeutics (AXSM) had 49,236,365 shares outstanding at the time of the filing.

What was the average price per share of AXSM insider sales in June 2025?

Based on the reported transactions, Hunter R. Murdock's sales averaged approximately $101.50 per share across four transactions from June 16-20, 2025, with gross proceeds ranging from $751,975 to $768,503 for each 7,500-share block.
Axsome Therapeut

NASDAQ:AXSM

AXSM Rankings

AXSM Latest News

AXSM Latest SEC Filings

AXSM Stock Data

7.53B
41.82M
15.87%
77.48%
7.03%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK